UNSPSC 51151627: Chlorbenzoxamine

This classification denotes an antimuscarinic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N52918SLYN. European Medicines Agency schedules Chlorbenzoxamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06176MIG. Chlorbenzoxamine generally arises in the molecular formula C27H31CLN2O.

UNSPSC 51151627 Chlorbenzoxamine is a Commodity code that sees little relevant recent activity aligned with its nominal scope. The two recent state and local opportunities tagged under this code—a Seminole County, Florida procurement for naloxone and drug deactivation systems, and a Texas Health and Human Services Commission request for information on direct-to-manufacturer prescription programs—do not reflect purchases of chlorbenzoxamine as a chemical or pharmaceutical intermediate. Naloxone is an opioid antagonist used in overdose response, and the Texas RFI addresses pharmacy benefit management and prescription fulfillment channels, neither of which maps to chlorbenzoxamine sourcing or supply. The code appears to be a mislabeling artifact rather than an active procurement category for the work actually being solicited.

The Seminole County opportunity (IFB 60459723LAS, due July 26, 2023) is the only solicitation with concrete delivery scope: 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, and a two-year initial term with optional one-year renewal. Bidders must provide unit costs, comply with drug-free workplace and E-Verify requirements, and carry workers' compensation and commercial general liability insurance; the contract may be FEMA-funded. The Texas HHS RFI (HHS0017013, response deadline April 3, 2026) is exploratory in nature, seeking vendor capabilities for direct manufacturer relationships outside traditional pharmacy benefit manager and group purchasing organization channels, with no award value, timeline, or formal evaluation criteria specified. Neither opportunity reflects actual chlorbenzoxamine procurement, and state and local buyers should verify code alignment before pursuing activity in this category.